Navigation Links
MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
Date:12/13/2007

Results to be presented at San Antonio Breast Cancer Symposium

AMSTERDAM, Netherlands, Dec. 13 /PRNewswire/ -- Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that an independent international consortium has demonstrated the prognostic power of its MammaPrint(R) breast cancer prognosis test in patients who have 1-3 positive lymph nodes. The data show that MammaPrint(R) can accurately identify a low risk group of lymph node-positive breast cancer patients with an excellent survival, implications that will help doctors to decide the optimal treatment management.

"Lymph node status is considered to be one of the most powerful prognostic factors for operable breast cancer, with a direct relationship between the number of positive nodes and disease outcome. However, approximately 30% of lymph node-positive patients will remain free of distant metastases without adjuvant chemotherapy," said Dr Laura van 't Veer, chief research officer at Agendia, who participated in the study. "Identifying patients with lymph node-positive disease who are at low risk of recurrence might lead to changes in guidelines for adjuvant chemotherapy."

In the current study, 241 tumor samples from breast cancer patients with 1-3 positive lymph nodes at 2 hospitals were selected and analyzed by the international TRANSBIG consortium. Patients that were classified as "high risk" for recurrence using MammaPrint(R) had significantly worse 5- and 10-year survival rates than those that were identified as "low risk." The numbers indicate that MammaPrint(R) has excellent prognostic power, even in patients having 1-3 positive lymph nodes. The entire study will be presented as an oral presentation at the San Antonio Breast Cancer Symposium on Thursday, December 13 in San Antonio, TX, USA.

"This study is in excellent agreement with our 2002 publication in the New England Journal of Medicine in which we also found that MammaP
'/>"/>

SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... (PRWEB) June 20, 2013 Conscires offer ... levels of interests and budgets., , ... on Scrum basics and the ScrumMaster role. In addition ... group activities and discussions on the necessary soft skills ... Scrum Team, and company-oriented Scrum implementation aspects. , ...
(Date:6/19/2013)... , June 19, 2013  U.S. Secretary of State ... at which distinguished Syngenta  scientist Mary-Dell Chilton ... 2013 World Food Prize. The prize is the foremost ... by improving the quality, quantity or availability of food ... other laureates were recognized for "revolutionary biotechnology discoveries that ...
(Date:6/19/2013)... -- Continuing its long history of proven clinical performance in ... Inc. announces the U.S. Food and Drug Administration (FDA) ... assay for use on its Access 2 immunoassay system. ... Coulter,s troponin I test for over 12 years ... to continue providing dependability to laboratories supporting emergency care," ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
Breaking Biology Technology:Presenting Agile and Scrum Private Trainings in Kansas by Conscires Agile Practices 2Syngenta's Mary-Dell Chilton named 2013 World Food Prize laureate 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... ST. LOUIS, Oct. 5 ISTO Technologies, Inc. (ISTO), ... regeneration, announced today the completion of patient enrollment in ... an injectable formulation of juvenile chondrocytes designed for the ... patients enrolled at two clinical sites. All patients enrolled ...
... Lake, N.Y. Given the many pressing concerns of the ... to lose sleep. But for those whose responsibility it is ... charged with that mission include scientists like medical researcher Steve ... develop a vaccine that will protect the public against weaponized ...
... (Nasdaq: AMGN ) today announced that results ... trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX ... metastatic colorectal cancer (mCRC), respectively, were published online in ... "Both studies demonstrated that Vectibix administered with chemotherapy ...
Cached Biology Technology:ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11
(Date:6/19/2013)... In the cover story for the journal ... at the University of Massachusetts Amherst describe a new ... study the function of individual proteins in individual cell ... should allow deeper insights into protein function, Chase says, ... what that single protein does when we isolate its ...
(Date:6/19/2013)... International Science Consortium (PISC) is extremely disappointed that ... has upheld a decision that requires Dow Benelux ... rats. The study will use approximately 1160 animals ... to the substance dipropylene glycol methyl ether acetate ... Community,s Regulation on the Registration, Evaluation, Authorisation and ...
(Date:6/19/2013)... Diversity Course at the Marine Biological Laboratory (MBL), ... in Microbiology site by the American Society for ... program recognizes institutions and the scientists who worked ... the science of microbiology. A ceremony unveiling ... scheduled for Saturday, June 22, 2013, at 4:30 ...
Breaking Biology News(10 mins):UMass Amherst researchers develop powerful new technique to study protein function 2UMass Amherst researchers develop powerful new technique to study protein function 3Microbial diversity course designated as a 'Milestones in Microbiology' site 2
... Nov. 17, 2011   Life Technologies Corporation ... that the company has introduced its GeneArt® Algae ... and expression systems for photosynthetic microalgae Chlamydomonas ... strains are model organisms for the study of ...
... -- Researchers have demonstrated that the employees at ... fruits and vegetables and get 50 percent more exercise ... participating in the WellSteps Turnkey Wellness Solution ... and sleep quality. Employees also demonstrated fewer hospital and ...
... might be considered a "performance enhancing" substance for athletes, ... Journal ( http://www.fasebj.org ) shows that these enhancements ... in the brain. According to the study, short- ... constricting arteries, which reduces the flow of blood to ...
Cached Biology News:GeneArt® Algae Engineering Kits by Life Technologies™ 2GeneArt® Algae Engineering Kits by Life Technologies™ 3New Study Shows Impact of Employee Wellness Efforts 2Biker's warning! EPO hits blood vessels to raise blood pressure in the brain 2
... Goat Immunogen: Goats were ... Antibody was isolated by affinity chromatography ... Goat anti- human T7 affinity purified antibodies ... bromide method. Specificity: ...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Biology Products: